A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cancer evolution
Chondrosarcoma
Genetics
Genomics
IDH1
IDH2
Sarcoma
TERT
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
30 08 2022
30 08 2022
Historique:
received:
02
11
2021
accepted:
07
07
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Central conventional chondrosarcoma (CS) is the most common subtype of primary malignant bone tumour in adults. Treatment options are usually limited to surgery, and prognosis is challenging. These tumours are characterised by the presence and absence of IDH1 and IDH2 mutations, and recently, TERT promoter alterations have been reported in around 20% of cases. The effect of these mutations on clinical outcome remains unclear. The purpose of this study was to determine if prognostic accuracy can be improved by the addition of genomic data, and specifically by examination of IDH1, IDH2, and TERT mutations. In this study, we combined both archival samples and data sourced from the Genomics England 100,000 Genomes Project (n = 356). Mutations in IDH1, IDH2, and TERT were profiled using digital droplet PCR (n = 346), whole genome sequencing (n=68), or both (n = 64). Complex events and other genetic features were also examined, along with methylation array data (n = 84). We correlated clinical features and patient outcomes with our genetic findings. IDH2-mutant tumours occur in older patients and commonly present with high-grade or dedifferentiated disease. Notably, TERT mutations occur most frequently in IDH2-mutant tumours, although have no effect on survival in this group. In contrast, TERT mutations are rarer in IDH1-mutant tumours, yet they are associated with a less favourable outcome in this group. We also found that methylation profiles distinguish IDH1- from IDH2-mutant tumours. IDH wild-type tumours rarely exhibit TERT mutations and tend to be diagnosed in a younger population than those with tumours harbouring IDH1 and IDH2 mutations. A major genetic feature of this group is haploidisation and subsequent genome doubling. These tumours evolve less frequently to dedifferentiated disease and therefore constitute a lower risk group. Tumours with IDH1 or IDH2 mutations or those that are IDHwt have significantly different genetic pathways and outcomes in relation to TERT mutation. Diagnostic testing for IDH1, IDH2, and TERT mutations could therefore help to guide clinical monitoring and prognostication.
Sections du résumé
BACKGROUND
Central conventional chondrosarcoma (CS) is the most common subtype of primary malignant bone tumour in adults. Treatment options are usually limited to surgery, and prognosis is challenging. These tumours are characterised by the presence and absence of IDH1 and IDH2 mutations, and recently, TERT promoter alterations have been reported in around 20% of cases. The effect of these mutations on clinical outcome remains unclear. The purpose of this study was to determine if prognostic accuracy can be improved by the addition of genomic data, and specifically by examination of IDH1, IDH2, and TERT mutations.
METHODS
In this study, we combined both archival samples and data sourced from the Genomics England 100,000 Genomes Project (n = 356). Mutations in IDH1, IDH2, and TERT were profiled using digital droplet PCR (n = 346), whole genome sequencing (n=68), or both (n = 64). Complex events and other genetic features were also examined, along with methylation array data (n = 84). We correlated clinical features and patient outcomes with our genetic findings.
RESULTS
IDH2-mutant tumours occur in older patients and commonly present with high-grade or dedifferentiated disease. Notably, TERT mutations occur most frequently in IDH2-mutant tumours, although have no effect on survival in this group. In contrast, TERT mutations are rarer in IDH1-mutant tumours, yet they are associated with a less favourable outcome in this group. We also found that methylation profiles distinguish IDH1- from IDH2-mutant tumours. IDH wild-type tumours rarely exhibit TERT mutations and tend to be diagnosed in a younger population than those with tumours harbouring IDH1 and IDH2 mutations. A major genetic feature of this group is haploidisation and subsequent genome doubling. These tumours evolve less frequently to dedifferentiated disease and therefore constitute a lower risk group.
CONCLUSIONS
Tumours with IDH1 or IDH2 mutations or those that are IDHwt have significantly different genetic pathways and outcomes in relation to TERT mutation. Diagnostic testing for IDH1, IDH2, and TERT mutations could therefore help to guide clinical monitoring and prognostication.
Identifiants
pubmed: 36042521
doi: 10.1186/s13073-022-01084-0
pii: 10.1186/s13073-022-01084-0
pmc: PMC9426036
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Subventions
Organisme : Wellcome Trust
ID : FC001202
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91(5):1063–72.
doi: 10.2106/JBJS.H.00416
Bovee J, Flanagan AM, Nielsen G, Akihiko Y, Bloem J. The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Soft Tissue and Bone Tumours. IARC Press. 2020.
Eefting D, Schrage YM, Geirnaerdt MJA, Le Cessie S, Taminiau AHM, Bovée JVMG, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50–7.
doi: 10.1097/PAS.0b013e31817eec2b
Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818–31.
doi: 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B
Fromm J, Klein A, Baur-Melnyk A, Knösel T, Lindner L, Birkenmaier C, et al. Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer. 2018;18(1):849.
doi: 10.1186/s12885-018-4741-7
Bovée JV, van der Heul RO, Taminiau AH, Hogendoorn PC. Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential: a report of 35 cases and a review of the literature. Cancer. 1999;86(9):1724–32.
doi: 10.1002/(SICI)1097-0142(19991101)86:9<1724::AID-CNCR14>3.0.CO;2-I
Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, et al. The epigenomics of sarcoma. Nat Rev Cancer. 2020;20(10):608–23.
doi: 10.1038/s41568-020-0288-4
Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43(12):1262–5.
doi: 10.1038/ng.994
Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, et al. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clin Sarcoma Res. 2017;7:8.
doi: 10.1186/s13569-017-0074-6
Hirata M, Sasaki M, Cairns RA, Inoue S, Puviindran V, Li WY, et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci U S A. 2015;112(9):2829–34.
doi: 10.1073/pnas.1424400112
Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, et al. Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes. PloS One. 2015;10(7):e0131998.
doi: 10.1371/journal.pone.0131998
Tarpey PS, Behjati S, Cooke S, Van Loo P, Wedge DC, Pillay N, et al. Frequent mutation of the major cartilage collagen gene, COL2A1, in chondrosarcoma. Nat Genet. 2013;45(8):923–6.
doi: 10.1038/ng.2668
Totoki Y, Yoshida A, Hosoda F, Nakamura H, Hama N, Ogura K, et al. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res. 2014;24(9):1411–20.
doi: 10.1101/gr.160598.113
Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE, et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun. 2013;4:2166.
doi: 10.1038/ncomms3166
Nicolle R, Ayadi M, Gomez-Brouchet A, Armenoult L, Banneau G, Elarouci N, et al. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nat Commun. 2019 Dec;10(1):4622.
doi: 10.1038/s41467-019-12525-7
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–43.
doi: 10.1002/path.2913
Amary MF, Ye H, Forbes G, Damato S, Maggiani F, Pollock R, et al. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Arch Int J Pathol. 2015 Feb;466(2):217–22.
doi: 10.1007/s00428-014-1685-4
Röpke M, Boltze C, Meyer B, Neumann HW, Roessner A, Schneider-Stock R. Rb-loss is associated with high malignancy in chondrosarcoma. Oncol Rep. 2006 Jan;15(1):89–95.
Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen A-M, Taminiau AHM, Hogendoorn PCW, et al. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med. 2009;13(9A):2843–52.
doi: 10.1111/j.1582-4934.2008.00406.x
Bovée JV, van Royen M, Bardoel AF, Rosenberg C, Cornelisse CJ, Cleton-Jansen AM, et al. Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am J Pathol. 2000;157(5):1587–95.
doi: 10.1016/S0002-9440(10)64796-7
Hallor KH, Staaf J, Bovée JVMG, Hogendoorn PCW, Cleton-Jansen A-M, Knuutila S, et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(8):2685–94.
doi: 10.1158/1078-0432.CCR-08-2330
Mandahl N, Johansson B, Mertens F, Mitelman F. Disease-associated patterns of disomic chromosomes in hyperhaploid neoplasms. Genes Chromosomes Cancer. 2012 Jun;51(6):536–44.
doi: 10.1002/gcc.21947
Olsson L, Paulsson K, Bovée JVMG, Nord KH. Clonal evolution through loss of chromosomes and subsequent polyploidization in chondrosarcoma. PloS One. 2011;6(9):e24977.
doi: 10.1371/journal.pone.0024977
Lin Y, Seger N, Chen Y, Hesla AC, Wejde J, Ghaderi M, et al. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality. Mod Pathol Off J U S Can Acad Pathol Inc. 2018;31(12):1834–41.
Lugowska I, Teterycz P, Mikula M, Kulecka M, Kluska A, Balabas A, et al. IDH1/2 mutations predict shorter survival in chondrosarcoma. J Cancer. 2018;9(6):998–1005.
doi: 10.7150/jca.22915
Zhu GG, Nafa K, Agaram N, Zehir A, Benayed R, Sadowska J, et al. Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(2):419–27.
doi: 10.1158/1078-0432.CCR-18-4212
Prendergast SC, Strobl A-C, Cross W, Pillay N, Strauss SJ, Ye H, et al. Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. J Pathol Clin Res. 2020;6(4):297–307.
doi: 10.1002/cjp2.174
Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018;24(361):k1687.
doi: 10.1136/bmj.k1687
Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994–1007.
doi: 10.1016/j.cell.2012.04.023
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinforma Oxf Engl. 2012;28(18):i333–9.
doi: 10.1093/bioinformatics/bts378
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81.
doi: 10.1038/nprot.2009.86
Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30(17):3894–900.
doi: 10.1093/nar/gkf493
Scrucca L, Fop M, Murphy TB, Raftery AE. mclust 5: clustering, classification and density estimation using Gaussian finite mixture models. R J. 2016;8(1):289–317.
doi: 10.32614/RJ-2016-021
Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 2011;1(2):137–43.
doi: 10.1158/2159-8290.CD-11-0028
Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, et al. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021;592(7853):302–8.
doi: 10.1038/s41586-021-03357-x
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94–101.
doi: 10.1038/s41586-020-1943-3
Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, et al. ChAMP: 450k chip analysis methylation pipeline. Bioinforma Oxf Engl. 2014;30(3):428–30.
doi: 10.1093/bioinformatics/btt684
Kolde R. pheatmap: Pretty heatmaps [Software]. URL HttpsCRAN R-Proj Orgpackage Pheatmap. 2015;
Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, et al. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest. 129(4):1801.
Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: drawing survival curves using ‘ggplot2’. 2021 . Available from: https://CRAN.R-project.org/package=survminer . (Cited 2021 Sep 15)
Pansuriya TC, Oosting J, Verdegaal SHM, Flanagan AM, Sciot R, Kindblom L-G, et al. Maffucci syndrome: a genome-wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes Cancer. 2011;50(9):673–9.
doi: 10.1002/gcc.20889
Zhang Y, Chen Y, Yang C, Seger N, Hesla AC, Tsagkozis P, et al. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma. Mod Pathol. 2021;9:1–8.
Tarpey PS, Behjati S, Young MD, Martincorena I, Alexandrov LB, Farndon SJ, et al. The driver landscape of sporadic chordoma. Nat Commun. 2017;8 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638846/ . (cited 2019 Sep 29).
Castresana JS, Barrios C, Gómez L, Kreicbergs A. Amplification of the c-myc proto-oncogene in human chondrosarcoma. Diagn Mol Pathol Am J Surg Pathol Part B. 1992;1(4):235–8.
doi: 10.1097/00019606-199203000-00035
Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, et al. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(36):9369–76.
doi: 10.1200/JCO.2005.03.7127
Lindström MS, Jin A, Deisenroth C, White Wolf G, Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol. 2007;27(3):1056–68.
doi: 10.1128/MCB.01307-06
Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029–1041.e21.
doi: 10.1016/j.cell.2017.09.042
Lucas C-HG, Grenert JP, Horvai A. Targeted next-generation sequencing identifies molecular and genetic events in dedifferentiated chondrosarcoma. Arch Pathol Lab Med. 2021;145(8):1009–17.
doi: 10.5858/arpa.2020-0379-OA
Lyskjaer I, Lindsay D, Tirabosco R, Steele CD, Lombard P, Strobl A-C, et al. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. J Pathol. 2020;252(2):151–64.
doi: 10.1002/path.5507
Steele CD, Tarabichi M, Oukrif D, Webster AP, Ye H, Fittall M, et al. Undifferentiated sarcomas develop through distinct evolutionary pathways. Cancer Cell. 2019;35(3):441–456.e8.
doi: 10.1016/j.ccell.2019.02.002
Campbell PJ, Getz G, Korbel JO, Stuart JM, Jennings JL, Stein LD, et al. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93.
doi: 10.1038/s41586-020-1969-6
Beird HC, Wu C-C, Ingram DR, Wang W-L, Alimohamed A, Gumbs C, et al. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Mol Case Stud. 2018;4(2):a002386.
doi: 10.1101/mcs.a002386
O’Malley DP, Opheim KE, Barry TS, Chapman DB, Emond MJ, Conrad EU, et al. Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature. Cancer Genet Cytogenet. 2001;124(2):105–11.
doi: 10.1016/S0165-4608(00)00335-6
Pathmanapan S, Ilkayeva O, Martin JT, Loe AKH, Zhang H, Zhang G-F, et al. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes. Cancer Metab. 2021;9(1):13.
doi: 10.1186/s40170-021-00247-8
Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402–7.
doi: 10.1038/ng.3441
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.
doi: 10.1056/NEJMoa0808710
Wang H-Y, Tang K, Liang T-Y, Zhang W-Z, Li J-Y, Wang W, et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res CR. 2016;31(35):86.
doi: 10.1186/s13046-016-0362-7
Kotredes KP, Razmpour R, Lutton E, Alfonso-Prieto M, Ramirez SH, Gamero AM. Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. Oncotarget. 2019;10(28):2675–92.
doi: 10.18632/oncotarget.26848